Shots:
- DeepCyte, a techbio startup focused on advancing AI-powered toxicology for drug development, has officially launched with $1.5 million in seed funding, introducing two solutions to help biopharma teams detect, predict, and understand drug toxicity in human cells at single-cell resolution
- DeepCyte’s MetaCore, a high-throughput single-cell metabolomics platform, leverages laser-based sampling and mass spectrometry to deliver detailed molecular insights, capturing cellular heterogeneity while generating AI-ready datasets with minimal sample preparation
- DeepCyte’s first AI solution, DeeImmuno, powered by MetaCore data and purpose-built ML, predicts toxicity classes, identifies biomarkers, and deciphers mechanisms, demonstrating 94% accuracy across 17 toxicity pathways in validation studies
Ref: PR Newswire | Image: DeepCyte |Press Release
Related News: C4 Therapeutics and Roche Enter Oncology Collaboration Worth Over $1B to Develop DAC with Payload
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
